2019
Hospital Prices Grew Substantially Faster Than Physician Prices For Hospital-Based Care In 2007–14
Cooper Z, Craig S, Gaynor M, Harish NJ, Krumholz HM, Van Reenen J. Hospital Prices Grew Substantially Faster Than Physician Prices For Hospital-Based Care In 2007–14. Health Affairs 2019, 38: 184-189. PMID: 30715987, DOI: 10.1377/hlthaff.2018.05424.Peer-Reviewed Original ResearchConceptsPhysician pricesHospital pricesHospital-based outpatient careHealth care spendingCare spendingTypes of pricesPrice growthHospital-based outpatient servicesProvider pricesReference pricingAntitrust enforcementPricesPolicy makersPricingSpendingOutpatient careRange of optionsGrowth rateGrowthPaymentsInpatient careOutpatient servicesInsurersMakersPercent
2017
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiology 2017, 2: 1369-1374. PMID: 29049467, PMCID: PMC5814995, DOI: 10.1001/jamacardio.2017.3655.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisDecision Support TechniquesDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaInsuranceInsurance, HealthInsurance, Health, ReimbursementMaleMarkov ChainsMiddle AgedMyocardial InfarctionPCSK9 InhibitorsQuality-Adjusted Life YearsStrokeUnited StatesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsCurrent pricesLife yearsPrivate payersAdditional quality-adjusted life yearPreliminary cost-effectiveness analysisCost-effectiveness standardsProbabilistic sensitivity analysesCost-effectiveness analysisPrivate payer perspectiveCost-effectiveness assessmentNegative returnsHealth system perspectiveSignificant discountUS dollarsDrug pricesPatent protectionPricesStatin treatment strategiesHealth insuranceTime horizonSubtilisin/kexin type 9 inhibitors